2022 Annual Meeting | Industry Therapeutic Update from Biohaven Pharmaceuticals: The Nurtec ODT: The First and Only Medication for the Acute and Preventive Treatment of Migraine

Date Monday 04/04/22

Time 07:00 PM - 10:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives In this Industry Therapeutic Update, we will explore the data behind Nurtec® ODT (rimegepant), the only medication approved to both treat and prevent migraine attacks.
Nurtec® ODT is the only oral therapy that offers patients flexible control over their migraine with a single medication.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN.

The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT	Speaker	Industry Therapeutic Update from Biohaven Pharmaceuticals: The Nurtec ODT: The First and Only Medication for the Acute and Preventive Treatment of Migraine

Faculty Disclosures
Eric J. Eross, DO	No disclosure on file